ACIST Medical Systems, a Bracco Group company, is launching the ACIST Pro Diagnostic System in select European markets.
The variable-rate contrast management system aims to advance precision, safety, and efficiency in image-guided cardiovascular procedures. This launch follows the company's receipt of the CE Mark under the European Medical Device Regulation (MDR).
ACIST Pro evolves from ACIST’s automated contrast delivery technology, ACIST CVi, which replaces manual with automated injection. The system was first introduced in Japan in 2025. Additional global availability is expected throughout 2026, with the company adding that 510(k) clearance from the U.S. Food and Drug Administration is pending.
